Long-term efficacy and safety of subcutaneous c1-inhibitor in elderly patients with hereditary angioedema type i/ii

Elderly patients ≥65 years old with hereditary angioedema (HAE) type I/II due to C1-inhibitor (C1-INH) deficiency may have an altered response to treatment and be at higher risk for treatment-related adverse events (AEs) due to comorbidities and polypharmacy. Subcutaneous (SC) C1-INH is indicated for routine prop hylaxis to prevent HAE attacks in adolescents and adults. This post-hoc analysis examined the efficacy and safety of C1-INH (SC) in patients ≥65 years old treated in an open-label extension study.

Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: J. Bernstein, L. Schwartz, H. Feuersenger, I. Pragst, J. Chiao, I. Jacobs Tags: P152 Source Type: research